393 related articles for article (PubMed ID: 20016538)
41. Clinical impact of minimal residual disease and genetic subtypes on the prognosis of childhood acute lymphoblastic leukemia.
Yu CH; Jou ST; Su YH; Coustan-Smith E; Wu G; Cheng CN; Lu MY; Lin KH; Wu KH; Chen SH; Huang FL; Chang HH; Wang JL; Yen HJ; Li MJ; Chou SW; Ho WL; Liu YL; Chang CC; Lin ZS; Lin CY; Chen HY; Ni YL; Lin DT; Lin SW; Yang JJ; Ni YH; Pui CH; Yu SL; Yang YL
Cancer; 2023 Mar; 129(5):790-802. PubMed ID: 36537587
[TBL] [Abstract][Full Text] [Related]
42. Treatment of childhood acute lymphoblastic leukemia with delayed first intrathecal therapy and omission of prophylactic cranial irradiation: Results of the TPOG-ALL-2002 study.
Yeh TC; Liang DC; Hou JY; Jaing TH; Lin DT; Yang CP; Peng CT; Hung IJ; Lin KH; Hsiao CC; Jou ST; Chiou SS; Chen JS; Wang SC; Chang TK; Wu KH; Sheen JM; Yen HJ; Chen SH; Lu MY; Li MJ; Chang TT; Huang TH; Chang YH; Chen SH; Yang YL; Chang HH; Chen BW; Lin PC; Cheng CN; Chao YH; Yang SH; Chao YY; Liu HC
Cancer; 2018 Dec; 124(23):4538-4547. PubMed ID: 30303520
[TBL] [Abstract][Full Text] [Related]
43. Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16.
Jeha S; Pei D; Choi J; Cheng C; Sandlund JT; Coustan-Smith E; Campana D; Inaba H; Rubnitz JE; Ribeiro RC; Gruber TA; Raimondi SC; Khan RB; Yang JJ; Mullighan CG; Downing JR; Evans WE; Relling MV; Pui CH
J Clin Oncol; 2019 Dec; 37(35):3377-3391. PubMed ID: 31657981
[TBL] [Abstract][Full Text] [Related]
44. Comparison of prognostic value of in vitro drug resistance and bone marrow residual disease on day 15 of therapy in childhood acute lymphoblastic leukemia.
Styczynski J; Piatkowska M; Jaworska-Posadzy A; Czyzewski K; Kubicka M; Kolodziej B; Kurylo-Rafinska B; Debski R; Pogorzala M; Wysocki M
Anticancer Res; 2012 Dec; 32(12):5495-9. PubMed ID: 23225457
[TBL] [Abstract][Full Text] [Related]
45. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber ALL Consortium Protocol 87-01.
LeClerc JM; Billett AL; Gelber RD; Dalton V; Tarbell N; Lipton JM; Barr R; Clavell LA; Asselin B; Hurwitz C; Schorin M; Lipshultz SE; Declerck L; Silverman LB; Cohen HJ; Sallan SE
J Clin Oncol; 2002 Jan; 20(1):237-46. PubMed ID: 11773175
[TBL] [Abstract][Full Text] [Related]
46. Improved survival of children with isolated CNS relapse of acute lymphoblastic leukemia: a pediatric oncology group study .
Ritchey AK; Pollock BH; Lauer SJ; Andejeski Y; Barredo J; Buchanan GR
J Clin Oncol; 1999 Dec; 17(12):3745-52. PubMed ID: 10577846
[TBL] [Abstract][Full Text] [Related]
47. [Evaluation of the efficacy of two successive protocols on pediatric acute lymphoblastic leukemia with E2A-PBX1 fusion gene].
Mei YY; Gao C; Cui L; Zhao XX; Zhao W; Li WJ; Wang KL; Jiang J; Zhang RD; Xie J; Shi HW; Wang B; Zhang YH; Ma XL; Zhou X; Wu MY; Li ZG
Zhonghua Er Ke Za Zhi; 2013 Jun; 51(6):467-71. PubMed ID: 24120066
[TBL] [Abstract][Full Text] [Related]
48. Clinical outcome of childhood lymphoblastic lymphoma in Shanghai China 2001-2010.
Gao YJ; Pan C; Tang JY; Lu FJ; Chen J; Xue HL; Zhai XW; Li J; Ye QD; Zhou M; Wang HS; Miao H; Qian XW; Xu Z; Meng JH
Pediatr Blood Cancer; 2014 Apr; 61(4):659-63. PubMed ID: 24243691
[TBL] [Abstract][Full Text] [Related]
49. Unexpected mortality from the use of E. coli L-asparaginase during remission induction therapy for childhood acute lymphoblastic leukemia: a report from the Taiwan Pediatric Oncology Group.
Liang DC; Hung IJ; Yang CP; Lin KH; Chen JS; Hsiao TC; Chang TT; Pui CH; Lee CH; Lin KS
Leukemia; 1999 Feb; 13(2):155-60. PubMed ID: 10025887
[TBL] [Abstract][Full Text] [Related]
50. [Multi-center trial based on SCMC-ALL-2005 for children's acute lymphoblastic leukemia].
SHAQ Multicenter Study Group of Children's Acute Lymphoblastic Leukemia Research
Zhonghua Er Ke Za Zhi; 2013 Jul; 51(7):495-501. PubMed ID: 24267129
[TBL] [Abstract][Full Text] [Related]
51. Differing Outcomes of Patients with High Hyperdiploidy and ETV6-RUNX1 Rearrangement in Korean Pediatric Precursor B Cell Acute Lymphoblastic Leukemia.
Lee JW; Kim S; Jang PS; Chung NG; Cho B
Cancer Res Treat; 2021 Apr; 53(2):567-575. PubMed ID: 33070555
[TBL] [Abstract][Full Text] [Related]
52. Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia.
Pui CH; Pei D; Sandlund JT; Campana D; Ribeiro RC; Razzouk BI; Rubnitz JE; Howard SC; Hijiya N; Jeha S; Cheng C; Downing JR; Evans WE; Relling MV; Hudson M
J Clin Oncol; 2005 Nov; 23(31):7936-41. PubMed ID: 16258093
[TBL] [Abstract][Full Text] [Related]
53. Risk-adjusted therapy for pediatric non-T cell ALL improves outcomes for standard risk patients: results of JACLS ALL-02.
Hasegawa D; Imamura T; Yumura-Yagi K; Takahashi Y; Usami I; Suenobu SI; Nishimura S; Suzuki N; Hashii Y; Deguchi T; Moriya-Saito A; Kato K; Kosaka Y; Hirayama M; Iguchi A; Kawasaki H; Hori H; Sato A; Kudoh T; Nakahata T; Oda M; Hara J; Horibe K;
Blood Cancer J; 2020 Feb; 10(2):23. PubMed ID: 32107374
[TBL] [Abstract][Full Text] [Related]
54. Advances in therapy for childhood non-B-lymphoblastic leukaemia.
Rivera GK
Baillieres Clin Haematol; 1994 Jun; 7(2):273-98. PubMed ID: 7803902
[TBL] [Abstract][Full Text] [Related]
55. High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.
Cario G; Rhein P; Mitlöhner R; Zimmermann M; Bandapalli OR; Romey R; Moericke A; Ludwig WD; Ratei R; Muckenthaler MU; Kulozik AE; Schrappe M; Stanulla M; Karawajew L
Haematologica; 2014 Jan; 99(1):103-10. PubMed ID: 23911702
[TBL] [Abstract][Full Text] [Related]
56. Clinical outcomes of pediatric patients with newly diagnosed rhabdomyosarcoma treated by two consecutive protocols - A single institution report in Taiwan.
Chou SW; Chang HH; Lu MY; Yang YL; Lin DT; Lin KH; Jou ST
J Formos Med Assoc; 2019 Jan; 118(1 Pt 2):332-340. PubMed ID: 29903549
[TBL] [Abstract][Full Text] [Related]
57. The effect of central nervous system involvement and irradiation in childhood acute lymphoblastic leukemia: Lessons from the NOPHO ALL-92 and ALL-2000 protocols.
Taskinen M; Oskarsson T; Levinsen M; Bottai M; Hellebostad M; Jonsson OG; Lähteenmäki P; Schmiegelow K; Heyman M
Pediatr Blood Cancer; 2017 Feb; 64(2):242-249. PubMed ID: 27748030
[TBL] [Abstract][Full Text] [Related]
58. Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy.
Pui CH; Pei D; Raimondi SC; Coustan-Smith E; Jeha S; Cheng C; Bowman WP; Sandlund JT; Ribeiro RC; Rubnitz JE; Inaba H; Gruber TA; Leung WH; Yang JJ; Downing JR; Evans WE; Relling MV; Campana D
Leukemia; 2017 Feb; 31(2):333-339. PubMed ID: 27560110
[TBL] [Abstract][Full Text] [Related]
59. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital.
Pui CH; Sandlund JT; Pei D; Campana D; Rivera GK; Ribeiro RC; Rubnitz JE; Razzouk BI; Howard SC; Hudson MM; Cheng C; Kun LE; Raimondi SC; Behm FG; Downing JR; Relling MV; Evans WE;
Blood; 2004 Nov; 104(9):2690-6. PubMed ID: 15251979
[TBL] [Abstract][Full Text] [Related]
60. Non hodgkin's lymphoma seven years following remission of acute lymphoblastic leukemia.
Bakhshi S; Jain P; Anand M; Padmanjali K; Kumar R; Arya LS
Indian J Pediatr; 2004 May; 71(5):431-2. PubMed ID: 15163874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
